Search Results

You are looking at 31 - 40 of 420 items for :

  • "single agent" x
Clear All
Full access

Matthias Holdhoff and Marc C. Chamberlain

performance status (ECOG 0-2) to 3 different single-modality treatment arms: 1) standard radiation (60 Gy in 30 fractions), 2) hypofractionated radiation (34 Gy in 10 fractions), or 3) single-agent, standard-dose temozolomide (150-200 mg/m 2 /d for 5 days

Full access

Jessica A. Davis, Zhanglin Lin Cui, Madiha Ghias, Xiaohong Li, Robert Goodloe, Astra M. Liepa, Kenyon Ogburn and Lisa M. Hess

(95% CI: 12.07, 13.6). The most common 1L regimens were fluoropyrimidine + oxaliplatin (n=651, 22.4%), platinum (ie, cisplatin or carboplatin) + taxane (n=511, 17.5%), and single-agent fluoropyrimidine (n=280, 9.6%). 1,230 patients received second line

Full access

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad and Andrea Wahner Hendrickson

: Literature search was performed using Ovid MEDLINE, EMBASE, CENTRAL, and Scopus (inception through October 26, 2018). Eligible studies were phase 3, randomized, controlled trials that compared single agent PARPi to placebo or standard treatment. Number of

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn and Alan P. Venook

knowledge, of successful single-agent treatment of HER2 -amplifed CRC with trastuzumab-DM1. Clinical trials targeting patients with HER2 -mutated and -amplified metastatic colon cancer are currently underway. Molecular insights from investigating HER2

Full access

Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente and Francisco Ayala de la Peña

for statistical analysis. Results Patient Characteristics and Treatment Between March 2007 and December 2012, a total of 296 consecutive patients with breast cancer were treated with single-agent wP (80–100 mg/m 2 /week, 1-hour infusion

Full access

David D. Chism

second-line treatment based on a phase III trial demonstrating a 2-month survival benefit over best supportive care (BSC). 11 Salvage single agents produce a modest overall response rate (ORR) between 10% to 20%, median PFS of 2 to 3 months, and median

Full access

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson and Steven J. Cohen

distinguish tumor histology and were mostly performed in the era of single-agent 5-fluorouracil (5-FU). More recent case series have included patients receiving combination chemotherapy, and suggested response rates and outcomes more in line with those

Full access

Katherine M. Bever and Dung T. Le

. N Engl J Med 2012 ; 366 : 2455 – 2465 . 7. Brahmer JR Drake CG Wollner I . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic

Full access

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades and Kenneth C. Anderson

, MIP-1 alpha and angiogenic cytokines [abstract] . Haematologica 2006 ; 91 ( Suppl 1 ): 84 . Abstract 223 . 30. Barlogie B Desikan R Eddlemon P . Extended survival in advanced and refractory multiple myeloma after single-agent

Full access

Margaret von Mehren

Medical management of soft tissue sarcomas (STS) has been restricted by the limited availability of active drugs. A plethora of new oncologic agents are now available, many of which have specific therapeutic targets. Gemcitabine and docetaxel is a combination of drugs that have limited single-agent activity. Yondelis, a novel chemotherapeutic that binds DNA and functions partially by inhibiting transcription, is being tested alone and in combination with doxorubicin. Inhibitors of mTOR, a serine/threonine kinase that regulates cell cycle activation and cell growth, are also being tested. Growth factor receptor inhibitors are being evaluated in a variety of sarcomas that have been found to express the targets. In addition, a variety of agents are being assessed in gastrointestinal stromal tumors (GIST). Single agents and agents combined with imatinib are being tested in imatinib-refractory and in metastatic GIST. The increased use of targeted agents underscores the need for understanding sarcoma biology.